Question explored with the scientific record
Conversation so far
- 1 how safe is shingrix
- 2 How does Shingrix compare to Zostavax in safety and effectiveness?
Answered on this page ↓
How does Shingrix compare to Zostavax in safety and effectiveness?
Shingrix is more effective than Zostavax but carries a higher burden of short-term side effects; the safety gap on serious harms is narrower than the efficacy gap.
The effectiveness difference is large. In the pivotal trials, Shingrix showed about 97% efficacy against shingles in adults 50+ and 90% in those 70+, while Zostavax reduced shingles by about 51% in adults 60+ [1][3]. Real-world studies confirm the gap: Shingrix effectiveness was about 70% after two doses in Medicare beneficiaries 65+, while Zostavax effectiveness was about 49% in year one, dropping to 32% by year eight [1][5].
| Comparison | Shingrix (RZV) | Zostavax (ZVL) |
|---|---|---|
| Efficacy, adults 50+ | 97% [3] | Not studied at 50-59 |
| Efficacy, adults 60+ | ~90% [3] | 51% [1] |
| Real-world effectiveness, 65+ | 70% (two doses) [1] | 49% year 1, 32% year 8 [5] |
| Serious AE reports in VAERS | 2.9% of reports [4] | 27.6% of reports [4] |
| Herpes zoster in VAERS reports | 5.5% of reports [4] | 61.6% of reports [4] |
The safety comparison is more nuanced. The higher serious AE rate for Zostavax in VAERS (27.6% vs 2.9%) is almost entirely driven by reports of shingles and vesicular rash after the live vaccine — these are expected manifestations of the live virus, not unexpected harms [4]. Shingrix causes far more short-term reactogenicity: local reactions were 7 times more common than placebo, and severe local reactions 31 times more common [2]. Both vaccines carry a small Guillain-Barré syndrome signal, estimated at about 3 excess cases per million Shingrix doses [1].
My call: Shingrix is clearly more effective than Zostavax, especially in older adults, and the live vaccine's safety profile in VAERS is inflated by reports of breakthrough shingles. But Shingrix causes substantially more short-term pain and fever. For most people over 50, the effectiveness advantage probably outweighs the reactogenicity. Confidence: moderate.
Sources used 5
-
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
A Markov-based cost-effectiveness analysis demonstrates that the adjuvanted recombinant zoster vaccine (RZV) is cost-effective versus no vaccination and cost-saving versus ZVL for US adults aged 60+, using a 1-million-person lifetime cohort and US population data.
DOI: 10.1016/j.vaccine.2018.07.005 -
P-112. Characterization of Herpes Zoster Cases and Sustained High Vaccine Efficacy Against Herpes Zoster Complications in Individuals Vaccinated with Recombinant Zoster Vaccine During A Long-Term Follow-Up Study
In ZOE-LTFU, recombinant zoster vaccine maintained high efficacy against herpes zoster complications over long-term follow-up: 87.5% against post-herpetic neuralgia and 91.7% against non-PHN complications; the few breakthrough cases still commonly reported pain.
DOI: 10.1093/ofid/ofae631.319 -
Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024
In 69,822 US VAERS reports (2017-2024), herpes zoster vaccine adverse-event reporting was dominated by transient reactogenicity and injection-site reactions, with serious reports uncommon overall (6.6%) and for Shingrix (2.9%) but more frequent for Zostavax (27.6%), largely driv…
DOI: 10.3389/fmed.2026.1920596 -
Herpes zoster vaccination efficacy in the long-term care facility population: a qualitative systematic review
A qualitative systematic review synthesizing evidence on herpes zoster vaccination efficacy in adults over 60 residing in long-term care facilities, finding overall vaccine efficacy and safety signals across LTCF and community settings, but noting limited LTCF-specific data and …
DOI: 10.1080/03007995.2019.1600482